首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 234 毫秒
1.
应用放射免疫分析法(RIA)检测53例急性白血病(AL)患者血浆内皮素(ET)水平,以探讨其血浆ET变化的临床意义。结果显示:AL组血浆ET水平为(99.92±l2.32)ng/L,明显高于正常对照组[(62.28±8.91)ng/L,P<0.01]。化疗达完全缓解者血浆ET水平为(73.53±8.42)ng/L,较未缓解组明显下降(P<0.01)。AL并出血的轻、中度组血浆ET水平明显高于无出血组(P<0.05),而重度出血组血浆ET水平却显著低于无出血组和轻、中度出血组(均为P<0.01)。AL血浆ET水平与骨髓白血病细胞比例呈正相关(r=0.9065,P<0.01).提示AL血浆ET水平明显升高,并与病情演变及转归密切相关。  相似文献   

2.
用放射免疫法检测80例充血性心力衰竭(CHF)患者血浆肾上腺髓质素(AM)含量,同时分析了血浆AM与左室射血分数(LVEF)和心胸比率的相关性,以观察不同程度CHF患者血浆AM含量变化,并探讨其临床意义。结果发现:①CHF患者血浆AM含量(50.64±23.12)ng/L,明显高于正常人(16.82±4.48)ng/L,P<0.001;②血浆AM水平与心力衰竭严重程度相平行,心衰程度越严重,AM水平越高;③血浆AM与LVEF呈显著负相关(r=-0.6258,P<0.001),与心胸比率呈显著正相关(r=0.6037,P<0.001)。提示,AM参与了CHF的病理生理过程,血浆AM水平可作为反映心力衰竭严重程度的一项指标  相似文献   

3.
目的:探讨充血性心力衰竭(CHF)与血浆内皮素(ET)之间的关系和意义,以及卡托普利治疗对CHF和血浆ET的影响。方法:用放射免疫法(RIA)测定42例CHF患者卡托普利治疗前后血浆ET浓度,23例健康老年者血浆ET浓度做为对照组。结果:42例CHF患者治疗前血浆ET浓度626±08pg/ml明显高于对照组(408±06pg/ml,P<0001),随心力衰竭程度加重而血浆ET升高,心功能Ⅳ级(702±101pg/ml)>Ⅲ级(621±08pg/ml)>Ⅱ级(521±057pg/ml),各组间比较差异显著。加用卡托普利治疗4周后,心功能改善,ET浓度为510±072pg/ml,与治疗前比较差异显著(P<001)。结论:ET参与了心衰的病理过程,其血浆浓度与心衰程度一致。卡托普利显著改善心功能可能与降低血浆ET浓度密切相关  相似文献   

4.
目的 研究甲亢病人的钙磷代谢、骨代谢和骨密度改变及机理。方法 对38 例甲亢病人治疗前后用单能 C T( S E Q C T) 测定骨密度( B M D) 变化,用双抗体法测定血Ⅰ型胶原羧基端前肽( C I C P) ,骨钙素( B G P) 和尿脱氧吡啶酚( D P D) 排泄率的变化。结果 治疗前 B M D 明显降低[ 男(120±8) mg/cm 3 H A,女(114 ±7 .2) m g/cm 3 H A] 治疗后都恢复正常。血 B G P 男性从(15 .2 ±7 .9)μg/ L 下降到(7 .5 ±2 .8)μg/ L( P< 0 .05) ,女性从(16 .4 ±7 .1)μg/ L 下降到(6 .8 ±2 .1) μg/ L( P< 0 .01) 。血 C I C P 男性从(185 ±23 .5)ng/ ml 下降到(70 ±10 .4)ng/ ml( P< 0 .05) ,女性从(164 ±16 .2)ng/ ml 下降到(69 ±9 .2)ng/ ml( P< 0 .05) 。尿 D. P. D 男性从(13 .7 ±2 .5)n M/ m M 下降到(3 .4 ±1 .0) n M/ m M( P< 0 .01) ,女性从(14 .6 ±2 .3)n M/ m M 下降到(4 .5 ±1 .2  相似文献   

5.
目的:探讨肝细胞生长因子/扩散因子( H G F/ S F)、转化生长因子β( T G Fβ)在结核性胸腔积液( T B P E)中的表达,寻找诊断结核性胸膜炎的特异性标记。方法:用 H G F/ S F E L I S A 药盒和生物法测定32 例胸腔积液中 H G F/ S F和 T G Fβ水平,并对 T B P E组中10 例病人同时作血清 H G F/ S F、 T G Fβ检测。结果: H G F/ S F在 T B P E中为7.5±7.3 ng/m l,高于非 T B P E的0.98±0.88 ng/m l( P< 0.05)。10 例 T B P E者的胸水和血清 H G F/ S F含量分别是10.9±6.6 ng/m l和1.9±1.7ng/m l( P< 0.002)。 T G Fβ在 T B P E中含量为27.3±11.1 ng/m l,高于其在血清中的含量3.9±3.3 ng/m l( P< 0.001),也高于对照血清的1.87±1.05 ng/m l( P> 0.05)。结论:在 T B P E中存在高水平 H G F/ S F、 T G Fβ。这可能与结核性肉芽肿形成有关,可能在促进胸膜纤维化及组织修复中有重要作用  相似文献   

6.
通过右心漂浮导管检测了20例临床缓解期慢性阻塞性肺病(COPD)患者的血流动力学参数,并用放射免疫分析法分别测定了体动脉和肺动脉血浆内皮素-1(ET-1)水平。结果显示:体动脉血浆ET-1水平(57.00±8.89)pg/ml小于肺动脉血浆ET-1水平(75.92±17.36)pg/ml(P<0.001):COPD并PAH组肺动脉混合静脉血浆ET-1水平的(83.90±17.12)pg/ml明显高于COPD非PAH组肺动脉混合静脉血浆ET-1水平(62.73±4.43)pg/ml(P<0.05);肺动脉混合静脉血浆ET-1水平与肺动脉平均压(PAPm)及肺血管阻力(PVR)呈显著的正相关(r=0.88,P<0.001;r=0.081,P<0.001),与心输出量(CO)、氧饱和度(SAT%)呈显著的负相关(r=-0.47,P<0.05:r=-0.79,P<0.001)。提示ET-1在COPD并PAH的发生发展中起着重要的病理生理学作用。  相似文献   

7.
用放射免疫分析法测定 40 例肺癌患者血清 I G FⅡ、 T G Fα、 G M  C S F水平,并与 20 例正常对照比较。21 例患者化疗后再次测定,观察化疗后的变化。结果表明,肺癌患者血清 T G Fα为 7.85±1.61ng/ L,明显高于对照组的 529±1.31ng/ L( P< 0.01); G M  C S F 为 127±0.33μg/ L,明显高于对照组 041±0.12,( P< 0.01);血清 I G FⅡ水平为 048±0.14μg/ L,与正常对照的 046±0.13μg/ L 无差异( P>005)。化疗后患者血清 G M  C S F明显升高( P< 001), I G FⅡ、 T G Fα无明显变化。  相似文献   

8.
应用放射免疫方法测定24例先天性心脏病(CHD)患者血浆内此素-1(ET-1)及骨源性类洋地黄素(EDLF)水平。结果显示:血浆ET-1水平CHD组明显高于正常对照组(P〈0.01),CHD-LR组明显高于CHD-RL组(P〈0.01);血浆EDLF水平CHD组明显低于正常对照组(P〈0.01),CHD-LR组略高于CHD-RL组(P〉0.05)。提示ET-1及EDLF在CHD的病理生理过程中起一  相似文献   

9.
目的:研究高血压病(esentialhypertension,EH)病人胰岛素抵抗(insulinresistance,ISR)与纤溶酶原激活物抑制物1(PAI1)的关系。方法:EH病人59例,正常对照46例。测定血浆PAI1、tPA(组织型纤溶酶原激活物)、空腹血糖(GLU)、胰岛素(INS)、低密度脂蛋白胆固醇(LDLC)、高密度脂蛋白胆固醇(HDLC)、甘油三酯(TG)、胰岛素敏感指数(ISI)、血尿酸(UA)、体重指数(BMI)、腹围/臀围比(WHR)等指标。结果:EH病人ISI(用空腹血糖与胰岛素乘积的倒数表示)较正常对照组下降(-5.4±0.5vs-39±0.8,P<0.01)。血浆PAI1较对照组升高[(29±8)mg·L-1vs(24±5)mg·L-1,P<0.01]。在高血压组中单相关分析表明PAI1与WHR(r=0.369,P<0.01)、GLU(r=0.563,P<0.001)正相关,与ISI(r=-0.301,P<0.05),HDLC(r=-0.417,P<0.01)、tPA(r=-0.499,P<0.001)负相关。以BMI、WHR、ISI、HDLC、LDL  相似文献   

10.
一氧化氮合成抑制剂对犬体内外内皮素-1分泌的影响   总被引:6,自引:0,他引:6  
研究了一氧化氮在整体动物及培养的内皮细胞对内皮素-1分泌的影响。用药前缺氧时麻醉犬的肺动脉平均压(mPAP)、肺血管阻力(PVR)及股动脉血浆内皮素-1(ET一1)分别为3.3±0.4kPa(1mmHg=0.133kPa)、68.7±10.2kPa·s/L、47.2±17.4ng/L。用一氧化氮合成酶抑制剂NG-硝基-L-精氨酸甲酯(L-NAME)可使急性缺氧时的mPAP和PVR增加到4.9±0.6kPa和160.9±34.6kPa·s/L(P均<0.01),其作用维持3小时,用药后60、120、180分钟缺氧时的ET一1分别升高到68.2±20.6、72.8±20.9、75.8±22.7ng/L,P均<0.05。对人脐静脉内皮细胞的研究结果显示,10-11mol/L及10-7mol/LL-NAME均可显著增加培养基中的Er-1浓度(P<0.05)。结果提示一氧化氮可抑制缺氧性肺血管收缩及ET-1的分泌。  相似文献   

11.
Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P < 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (>0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P <0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P < 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.  相似文献   

12.
Objective: To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods: SD rats served as both donors and recipients. 4℃ sodium lactate Ringer's was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava (IVC) inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results: Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion: This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.  相似文献   

13.
FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…  相似文献   

14.
Objective To observe blood pressure change with age in salt-sensitive teenagers whose salt sensitivity were determined by repeated testing.Methods Salt sensitivity was determined through intravenous infusion of normal saline combined with volume-depletion by oral diuretic furosemide in 55 teenagers. After five years, salt sensitivity was re-examined and subject blood pressure was followed up. Blood pressure changes in salt-sensitive teenagers were compared to that of non-salt sensitive teenagers over five years.Results After 5 years, the repetition rate of salt sensitivity determined by intravenous saline loading is 92.7%. In teenagers with salt sensitivity on the baseline, both the systolic blood pressure increments and increment rates were much higher than non-salt sensitive teenagers (12.7±12.1 mmHg vs. 2.8±5.2 mmHg, P< 0.01; 12.2%± 12.0% vs. 2.5% ±4.4%, P< 0.001,respectively). There was a similar trend for diastolic blood pressure (8.4 ± 6.4 mmHg vs. 3.7 ± 6.4 mmHg, P = 0.052; 13.2% ±10.6 % vs. 6.8%± 10.1%, P = 0.053, respectively).Conclusions Salt sensitivity determined by intravenous saline loading showed good reproducibility. Blood pressure increments with age were much higher in salt-sensitive teenagers than non-salt sensitive teenagers, especially in terms of systolic blood pressure.  相似文献   

15.
Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.  相似文献   

16.
In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.  相似文献   

17.
Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.  相似文献   

18.
目的:评价使用安心颗粒对急诊经皮冠状动脉介入术(PPCI)术后生活质量的影响.方法:将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组(术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次)和对照组(仅接受基础药物治疗).所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表(MIDAS)、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果:入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异(P>0.05);出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低(P<0.05);组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低(P<0.05).两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血(P>0.05).两组发生轻度血小板减少症的患者数比较无差异(P>0.05).结论:PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.  相似文献   

19.
Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P<0.01);the MAP decreased(P<0.01)and the HR increased drastically(P<0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.  相似文献   

20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号